HIV virus being released from the surface of an infected cell. Credit: Bette Korber at Los Alamos National Laboratory.

ViiV Healthcare has submitted applications seeking approval from US and European regulators for a 5mg dispersible-tablet (DT) formulation of its dolutegravir (DTG) drug to treat children with human immunodeficiency virus (HIV) infection.

The company is also seeking the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) authorisations for simplified dosing regimen intended to enable child-friendly use of the existing 50mg DTG film-coated tablet (FCT).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

DTG is an integrase strand transfer inhibitor (INSTI) that binds to the integrase active site, blocking the strand transfer step in retroviral deoxyribonucleic acid (DNA) integration required for HIV replication.

The drug is indicated for use in combination with antiretroviral (ARV) agents to treat HIV. If approved, the dispersible tablet formulation of DTG will be the first-of-its-kind accessible for paediatric patients.

ViiV Healthcare CEO Deborah Waterhouse said: “For parents living in resource-poor countries, the ability to give medicine to children in a format that they can swallow and tolerate can mean the difference between life and death.

“By submitting these files to regulators for approval, we believe that we are on the cusp of delivering against our promise to develop dolutegravir in a tablet that can be dispersed simply in water. We will then aim to make this available, via partnerships, as quickly as possible to children living with HIV worldwide.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Regulatory applications include results from ongoing P1093 and ODYSSEY (PENTA20) clinical trials conducted in patients aged four weeks to 18 years.

P1093 involves sites in the US, South Africa, Brazil, Zimbabwe, Thailand and Malawi, while ODYSSEY is occurring in Europe, Thailand, South Africa, Uganda, South America and Zimbabwe.

Through a voluntary licensing policy, ViiV allows companies to produce and sell generics of paediatric DTG royalty-free in least-developed, low-income, lower-middle-income and sub-Saharan African countries. The licence is also applicable in some upper-middle-income countries.